These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 22916844)
41. Dual antiplatelet therapy after drug-eluting stents--how long to treat? Colombo A; Chieffo A N Engl J Med; 2014 Dec; 371(23):2225-6. PubMed ID: 25399657 [No Abstract] [Full Text] [Related]
42. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335 [TBL] [Abstract][Full Text] [Related]
43. CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance. Rai M; Seip RL; Gupta A; McKay RG; Hirst J; Thompson PD; Ruaño G Conn Med; 2012 May; 76(5):267-72. PubMed ID: 22685981 [TBL] [Abstract][Full Text] [Related]
44. [Genetic variability in the efficacy of clopidogrel]. Kristensen KE; Rasmussen HB; Hansen PR Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885 [TBL] [Abstract][Full Text] [Related]
45. Platelet function profiles in the elderly: results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. Capranzano P; Tamburino C; Capodanno D; Miccichè E; D'Urso L; Calvi V; Angiolillo DJ; Tamburino C Thromb Haemost; 2011 Dec; 106(6):1149-57. PubMed ID: 22011914 [TBL] [Abstract][Full Text] [Related]
46. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. Price MJ; Murray SS; Angiolillo DJ; Lillie E; Smith EN; Tisch RL; Schork NJ; Teirstein PS; Topol EJ; J Am Coll Cardiol; 2012 May; 59(22):1928-37. PubMed ID: 22624833 [TBL] [Abstract][Full Text] [Related]
47. Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Loh JP; Pendyala LK; Kitabata H; Torguson R; Chen F; Kent KM; Satler LF; Suddath WO; Pichard AD; Waksman R Am J Cardiol; 2013 Mar; 111(6):841-5. PubMed ID: 23273719 [TBL] [Abstract][Full Text] [Related]
48. Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness. Franken CC; Kaiser AF; Krüger JC; Overbeck K; Mügge A; Neubauer H Thromb Haemost; 2013 Jul; 110(1):131-40. PubMed ID: 23615745 [TBL] [Abstract][Full Text] [Related]
49. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009 [TBL] [Abstract][Full Text] [Related]
50. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Namazi S; Kojuri J; Khalili A; Azarpira N Biochem Pharmacol; 2012 Apr; 83(7):903-8. PubMed ID: 22265638 [TBL] [Abstract][Full Text] [Related]
51. Clopidogrel pretreatment of patients with ST-elevation myocardial infarction does not affect platelet reactivity after subsequent prasugrel-loading: platelet reactivity in an observational study. Nührenberg TG; Trenk D; Leggewie S; Ristau I; Amann M; Stratz C; Hochholzer W; Valina CM; Neumann FJ Platelets; 2013; 24(7):549-53. PubMed ID: 23216528 [TBL] [Abstract][Full Text] [Related]
52. Cytochrome p-450 polymorphisms and response to clopidogrel. Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias W; Braunwald E; Sabatine MS N Engl J Med; 2009 Jan; 360(4):354-62. PubMed ID: 19106084 [TBL] [Abstract][Full Text] [Related]
54. Timing of thienopyridine loading and outcomes in the TRITON trial: the FDA Prasugrel Action Package outlook. Serebruany VL Cardiovasc Revasc Med; 2011; 12(2):94-8. PubMed ID: 21421187 [TBL] [Abstract][Full Text] [Related]
55. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759 [TBL] [Abstract][Full Text] [Related]
56. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Bonello-Palot N; Armero S; Paganelli F; Mancini J; De Labriolle A; Bonello C; Lévy N; Maillard L; Barragan P; Dignat-George F; Camoin-Jau L; Bonello L Am J Cardiol; 2009 Dec; 104(11):1511-5. PubMed ID: 19932784 [TBL] [Abstract][Full Text] [Related]
57. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678 [TBL] [Abstract][Full Text] [Related]
58. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445 [TBL] [Abstract][Full Text] [Related]
59. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. Beigel R; Fefer P; Rosenberg N; Novikov I; Elian D; Fink N; Segev A; Guetta V; Hod H; Matetzky S Am J Cardiol; 2013 Nov; 112(10):1551-6. PubMed ID: 23972349 [TBL] [Abstract][Full Text] [Related]
60. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]